News for Celltrion, Inc. (068270.KS)

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The availability of the first omalizumab biosimilar will help increase access and potentially lower the healthcare cost for people with asthma and allergic diseases JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2]

PR NewswireJERSEY CITY, N.J., March 3, 2025 STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of referenc

PR NewswireINCHEON, South Korea, Jan. 14, 2025 Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy an

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio and building on Celltrion's expertise in immunology STEQEYMA is expected to be marketed in the U.S. in February 2025 JERSEY CITY, N.J., Dec. 18, 2024 /PRNewswire/ -- Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.[1]

Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkvi

Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby equity purchase agreement, to raise an additional $2 million in debt financing and the sale of up to 500,000 shares of common stock pursuant to forward purchase agreement Financing will support advancement of Abpro's pipeline of its next-generation antibody therapies for cancer, ophthalmology, and infectious diseases WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ('Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II ('ACAB”), a special purpose acquisition company, with a Nasdaq bell ringing ceremony. Abpro also celebrated the consummation of a PIPE offering raising $7 million in gross proceeds and a $2.76 million convertible note financing with YA II PN, LTD ('Yorkville”) to cover expenses in connection with the closing of the business combination.

The U.S. Inflammatory Bowel Disease Treatment Market Size sector reached a market value of USD 9.37 billion in 2022. Future projections show a bright outlook, with a Compound Annual Growth Rate…

As per Fortune Business Insights’ report, the respiratory syncytial virus therapeutics Market share sector attained a worth of USD 609.2 Million in 2020. Forecasts indicate a promising path…

Atlantic Coastal extends merger deadline to October 19

Atlantic Coastal enters key agreements ahead of merger

As per Fortune Business Insights’ report, the us biosimilars Market share sector attained a worth of USD 6.73 Billion in 2021. Forecasts indicate a promising path, foreseeing a Compound Annual Growth…

Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. on July 2, 2023 Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions JERSEY CITY, N.J., Aug. 13, 2024 /PRNewswire/ -- Celltrion USA, Inc., (Celltrion USA) today announced its FDA-approved biosimilar adalimumab-aaty, has been added to the Costco member prescription program. Adalimumab-aaty is a high-concentration (100mg/mL) and citrate-free biosimilar to Humira® (adalimumab).

In this article, we discuss the 25 richest billionaires in healthcare industry.

Piramal Alternatives Trust acquires stake in Annapurna Finance, Bajaj Auto's Vice Chairman resigns, Magma Ventures sells shares of Poonawalla Fincorp, SBI Cards raises funds, CCEA approves coal-to-SNG project, Shilpa Medicare ordered to pay damages, Sarda Metals approves new project, Dhanuka Agritech signs Letter of Intent, Auro Laboratories acquires leasehold land, Catvision sells land & building, Gainwell Group acquires stake in TIL, Mastek collaborates with Microsoft, Kamat Hotels signs JDA, Tamil Nadu Transmission terminates contract, Borosil to raise funds through QIP.

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II GlobeNewswire January 22, 2024 WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing...

On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was approved Celltrion Group’s…

Here’s how Placental Growth Factors Help in Prediction, Diagnosis, and Treatment of Pre-eclampsia Conditions? FMI Predicts the Market to Surpass US$ 64.6...

/PRNewswire/ -- The "Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029" & "Pharmaceutical Excipients Global Market - Forecast To 2029"...

In this article, we will discuss the 15 most valuable Korean companies in the world.  You can skip our detailed analysis of these companies, and go directly to 5 Most Valuable Korean Companies in the...